You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 9,969,754

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,969,754 protect, and when does it expire?

Patent 9,969,754 protects EVRYSDI and is included in one NDA.

This patent has fifty-two patent family members in thirty-five countries.

Summary for Patent: 9,969,754

Patent landscape, scope, and claims:

Title:	Compounds for treating spinal muscular atrophy
Abstract:	The present invention provides compounds of formula (I) ##STR00001## wherein A, R.sup.1, R.sup.2 and R.sup.3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
Inventor(s):	Ratni; Hasane (Basel, CH), Green; Luke (Basel, CH), Weetall; Marla L. (South Plainfield, NJ), Naryshkin; Nikolai A. (South Plainfield, NJ)
Assignee:	HOFFMANN-LA ROCHE INC. (Little Falls, NJ) PTC THERAPEUTICS, INC. (South Plainfield, NJ)
Application Number:	15/351,267
Patent Claim Types: see list of patent claims	Use; Composition; Compound;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 9,969,754

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genentech Inc	EVRYSDI	risdiplam	FOR SOLUTION;ORAL	213535-001	Aug 7, 2020		RX	Yes	Yes	9,969,754	⤷ Subscribe	Y	Y		TREATMENT OF SPINAL MUSCULAR ATROPHY	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,969,754

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3143025	⤷ Subscribe	301128	Netherlands	⤷ Subscribe
European Patent Office	3143025	⤷ Subscribe	PA2021010	Lithuania	⤷ Subscribe
European Patent Office	3143025	⤷ Subscribe	2021C/537	Belgium	⤷ Subscribe
European Patent Office	3143025	⤷ Subscribe	CA 2021 00037	Denmark	⤷ Subscribe
European Patent Office	3143025	⤷ Subscribe	122021000051	Germany	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.